Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia

Br J Haematol. 2019 Jul;186(2):380-382. doi: 10.1111/bjh.15911. Epub 2019 Apr 7.
No abstract available

Keywords: ROR1; bispecific T cell engager; chronic lymphocytic leukaemia; ibrutinib; immunotherapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Neoplasm Recurrence, Local / immunology
  • Piperidines
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor Tyrosine Kinase-like Orphan Receptors / immunology*
  • T-Lymphocytes / immunology*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents, Immunological
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • ROR1 protein, human
  • Receptor Tyrosine Kinase-like Orphan Receptors
  • Adenine